logo
Letting banks loose is back on the agenda as UK politicians chase growth at any cost

Letting banks loose is back on the agenda as UK politicians chase growth at any cost

The Guardiana day ago

As the old ways of turning a profit become more difficult – from assembling cars to selling soap powder – politicians of all stripes want the City to inject some dynamism into the economy.
From Labour to Reform, the siren call of London's financial district is strong. If only, they ask, the wheels of the banking industry could be cranked to spin faster, surely much more money could be generated and we would all be rich.
While Rachel Reeves boasted of the huge benefit to economic growth from public investments in rail and renewable energy as central pillars of the government's spending review, in truth it is not enough to propel the economy forward.
To generate the kind of income that will pay for the next 30 years of an ageing society, plans to link Manchester and Liverpool by a marginally faster and more reliable train, though good in itself, is not the answer. The Treasury knows it is just an upgrade to existing services and will deliver only incremental returns.
To turbocharge growth, the chancellor wants private money to take the lead, partnering government to share the burden of building bridges and tunnels and spurring investments in whizzy new ventures.
And as a start, the Treasury wants the shackles taken off the bankers so they can become more inventive in the way they make money, taking risks that were previously frowned upon, if not banned, and rewarding themselves accordingly.
It is 18 years since Northern Rock's high-risk mortgage lending began to unravel and 17 years since Lehman Brothers went bust. Long enough, it seems, for memories to fade, and with them concerns about the damaging consequences of light-touch regulation.
That said, it's easy to see why the temptation to let the banks loose is back on the agenda. UK banks are among the most profitable in Europe and London plays host to the largest number of foreign banks. The UK's unicorn businesses – those privately held startup companies worth more than £1bn – rank in number behind only the US, India and China.
Some startups are considered to be at the forefront of the financial technology boom, including Revolut and Monzo. What could be better for Britain than to leverage a fintech industry that already has a worldwide reputation?
Revolut has championed handling funds invested in cryptocurrencies, and for this service, and its banking and wealth management, it has emerged as the most successful European fintech of the past decade. It was valued at $45bn last year. And there is no stopping the chief executive, co-founder and 25% owner, Nikolay Storonsky. He plans to expand into mortgages and consumer lending to challenge the major lenders, as well as growing in the US.
Monzo is the digital bank best known for its coral pink debit cards. After 10 years, the company announced its first profit last year, of £15.4m, after more than doubling revenues to almost £900m.
Reeves also wants pension funds to take more risks, which is a boon for an asset management industry that has fallen out of favour with the public in recent years due to its high charges and failure to deliver returns that better passive investments.
Last week, the House of Lords financial services regulation committee gave Labour's mission a boost. It attacked the main City watchdogs – the Financial Conduct Authority and the Prudential Regulation Authority – for having 'a deeply entrenched culture of risk aversion'. In a report that the Treasury will have privately welcomed, the committee said the regulators were partly to blame for holding back economic growth.
If the FCA and PRA, which have already pledged to reduce the paperwork and oversight of the City, become more trusting of its ability to manage risk, there is likely to be a sugar rush of activity, much as there was during the noughties.
Labour has helped get the ball rolling by lifting the bankers' bonus cap, to allow publicly listed banks to join the bonanza of rewards enjoyed by executives in Revolut and Monzo.
Monzo may have made only £15.4m profit but this modest sum was not to be re-invested. It was enough to warrant big payouts, including a £12m bag of cash and shares that Reuters said most likely went to the chief executive, TS Anil.
Underscoring how light-touch regulation is matched by executive pay bonanzas, a report last month by the jobs website eFinancialCareers found that bonuses in the UK's investment banks had risen by 26% year on year, beating their equivalents in Asia, Europe and the US. The average bonus payout for a City executive was about £110,000. And the trickle-down effect works in finance. At junior levels, bonuses increased by as much as 133%, the survey found.
Labour's backbench MPs know how this play ends. After all the partying and profit-making, there will be a severe hangover. And when that happens, the taxpayer is asked to save the day. Somehow, the profits of the financial sector belong to the bosses and the losses belong to the people.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada agrees to ratify Britain's accession to major trans-Pacific trade pact
Canada agrees to ratify Britain's accession to major trans-Pacific trade pact

Rhyl Journal

time8 minutes ago

  • Rhyl Journal

Canada agrees to ratify Britain's accession to major trans-Pacific trade pact

Ottawa will seek to introduce legislation to its parliament this autumn to formally approve Britain's entry to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP). The UK joined the bloc in 2024, but Canada is yet to ratify its accession – meaning Britain still faces pre-CPTPP trade barriers in exporting to the country. Following a bilateral meeting between the Prime Minister and his Canadian counterpart Mark Carney on Sunday, Downing Street said: 'Prime Minister Carney confirmed that Canada would ratify the UK's accession to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), seeking to introduce legislation to their parliament in the autumn. 'This will bring huge benefits to UK businesses by lowering tariffs when buying from and selling to Canada. 'They also agreed to set up a joint taskforce to turbocharge progress on other areas of mutual benefit, including technology and artificial intelligence – in support of shared growth and our national security. 'The taskforce will also look to make progress on the wider UK-Canada Free Trade Agreement.'

Work to get underway on 96 affordable homes in Sunderland
Work to get underway on 96 affordable homes in Sunderland

BBC News

time16 minutes ago

  • BBC News

Work to get underway on 96 affordable homes in Sunderland

Work on a £23.6m housing development of 96 affordable homes is due to get under East-based not-for-profit housing association, Thirteen Group, is building the homes off Amberley Street and Harrogate Street in Hendon in homes, which will all be available for affordable rent, will consist of 75 two, three and four-bedroom houses and 21 two-bedroom East Mayor Kim McGuiness said too many families had been "locked out of affordable housing for too long". 'Empty too long' The scheme is being supported by Homes England, the North East Mayor, Kim McGuinness, Sunderland City Council and local charity, Back on the development is supported by a £1.9m contribution from the North East Combined Authority's Brownfield Housing said: "Too many families have been locked out of affordable housing for too long so I'm pleased we'll be delivering even more schemes like this with a further £17m to transform brownfield sites with great homes for our communities across the region."Everyone deserves a good home." The development is expected to be completed by 2028. Council leader Michael Mordey, who is also the Hendon ward councillor, said: "I'm delighted to see the start of work on these much-needed homes for social rent in the heart of Hendon."This site has stood empty for far too long, so it really is great to finally see the development start," he added.

NHS faces paying more for US drugs to avoid future Trump tariffs
NHS faces paying more for US drugs to avoid future Trump tariffs

Telegraph

time26 minutes ago

  • Telegraph

NHS faces paying more for US drugs to avoid future Trump tariffs

Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Non-US countries are 'free-riding' Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store